Editor’s note: This story is developing and will be updated.
Dive Brief:
- Abbott has agreed to acquire cancer test-maker Exact Sciences for about $21 billion.
- Exact Sciences makes the Cologuard noninvasive screening test for colorectal cancer. The company also makes tests to detect multiple types of cancer early and identify molecular residual disease to assess the risk of recurrence.
- The deal is expected to close in the second quarter of 2026, subject to shareholder and regulatory approvals. Abbott expects Exact Sciences to generate more than $3 billion in revenue this year, and grow Abbott’s total diagnostics sales to more than $12 billion annually after the acquisition closes.
